Proteins and peptides have emerged in recent years to treat a wide range of multifaceted diseases such as cancer, diabetes and inflammation. The emergence of polypeptides has yielded advancements in the fields of biopharmaceutical production and formulation. Polypeptides often display poor pharmacokinetics, limited permeability across biological barriers, suboptimal biodistribution, and some proclivity for immunogenicity. Frequent administration of polypeptides is generally required to maintain adequate therapeutic levels, which can limit efficacy and compliance while increasing adverse reactions. Many strategies to increase the duration of action of therapeutic polypeptides have been described with many clinical products having been developed. This review describes approaches to optimise polypeptide delivery organised by the commonly used routes of administration. Future innovations in formulation may hold the key to the continued successful development of proteins and peptides with optimal clinical properties.

The aim of this study is to apply wet granulation on liquisolid powders to overcome issues of poor powder flowability and compressibility especially with using high viscosity liquid vehicles. Different liquisolid formulations were made using three excipients where the effect of each excipient used in the dissolution of the model hydrophobic drug (Glibenclamide) was evaluated. The Glibenclamide tablets were formulated using PEG 400, Synperonic PE/L44 and Cremophor ELP, at a 10 %w/w in liquid vehicle drug concentration. The carrier (Avicel®PH102) was used followed by colloidal silicon dioxide (coating material) that converted the wet mixture into dry powder. Potato starch, 5%w/w, as a disintegrant was mixed with the mixture manually for 10 minutes and was finalized by adding 0.75% of magnesium stearate as a lubricant. The final powder (depending on its flowability and compactability) was then compacted automatically using a single-punch tableting machine to give tablets with 4mg unit drug dose. Prepared liquisolid compacts were characterised via B.P. quality control tests. In this study, a novel discovery was achieved to overcome the major problems with liquisolid preparations (flowability and compactability). This new technique is the wet granulation process to be applied with liquisolid powders just before the compaction stage of the powders into tablets. Consequently, it was found that by application of wet granulation to liquisolid powder admixture, the large-scale production of liquisolid compacts is feasible and can be easily applied by pharmaceutical industry. As with some liquisolid vehicles especially high viscosity although very good to enhance dissolution usually formulations are studied in powder forms [1,2].Keywords: Liquisolid compacts; Granulation; Glibenclamide; Flowability and compactibility; Dissolution rate; Wettability Abstract Oral drug delivery is the main and most common route of administration. There are various types of dosage forms that can be formulated, and tablets are known to be the most common type. Tablets can be manufactured by several stages where the final stage is the compression of the powder held within a confined space. In addition, the use of tablets as dosage form became of interest to the pharmaceutical industry, thus the formulation of tablet with variety of forms were formulated [3]. Tablets are solid preparations each containing a single dose of one or more active ingredients and produced via compression of uniform volumes of particles. The secret behind the difference between each tablet is in the type of excipients used. Pharmaceutical industry use different excipients, diluents, disintegrants and lubricants to ensure that tablets of specified quality are prepared. However, one excipient can affect the properties of the tablets. Thus, it can be said that each excipient added has a specific role in the formulation of the oral tablets. ISSN: 2348-9782In addition, the In-vitro dissolution study found that granulated liquisolid tablets enhanced not only the flowability an...

No abstract

No abstract